Mechanism of Action
Triptorelin's dual mechanism, initial agonism then downregulation - determines how single-dose PCT use differs from chronic oncology use.
Initial Agonist Phase: LH/FSH Surge
A single bolus of triptorelin initially acts as a pure GnRH agonist, producing a large LH and FSH surge within 2-4 hours as pituitary GnRH receptors are briefly activated. This acute LH surge drives testicular testosterone production and initiates HPG axis re-activation. This is the PCT application, the flare response restarts a suppressed axis.[1]Chronic Agonism: Receptor Downregulation
With continued stimulation (depot formulations, repeated injections), pituitary GnRH receptors downregulate, LH and FSH fall to castrate levels, and testosterone drops to <50 ng/dL. This "chemical castration" is the mechanism for prostate cancer treatment. Single-dose PCT use terminates before this phase begins.[2]D-Trp6 Stability Advantage
The D-tryptophan at position 6 prevents peptidase degradation at the Gly6-Leu7 bond that rapidly cleaves native GnRH. This extends half-life from ~2-8 minutes (native GnRH) to 3-6 hours (aqueous triptorelin), providing sufficient duration for the initial LH surge without requiring depot formulation for the PCT application.[1]Research Overview
Prostate Cancer (FDA Approved)
Phase III ClinicalTriptorelin (Trelstar) depot formulations (3.75 mg monthly, 11.25 mg quarterly) achieve and maintain medical castration (testosterone <50 ng/dL) in advanced prostate cancer. FDA approval for this indication is based on large Phase III trials. Long-term hormonal suppression is the clinical goal - opposite to the single-dose PCT application.[1]
HPG Axis Restart (PCT Application)
Moderate EvidenceSingle-dose aqueous triptorelin (100 mcg SC) has been used as an off-label single-shot PCT protocol. Case reports and retrospective data show restoration of LH pulsatility, testosterone recovery, and testicular volume return within 4-8 weeks of a single injection after androgen suppression. This approach can compress standard 4-6 week PCT protocols into a single injection.[2]
Female Fertility Applications
Phase III ClinicalTriptorelin is FDA approved for female infertility (ovarian stimulation protocols, endometriosis treatment). Depot formulations produce ovarian suppression for IVF downregulation. The initial flare effect is managed in female fertility protocols to time follicular recruitment.[1]
Calculate your Triptorelin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| PCT HPG axis restart (single shot) | 100 µg | Single injection only | Subcutaneous |
| Conservative PCT dose | 50–75 µg | Single injection | Subcutaneous |
For PCT: administer approximately 2 weeks after last long-ester androgen dose (or 2-3 days after short-ester). Single injection only, do not repeat. The LH surge begins within 2-4 hours and peaks at 4-8 hours. Testosterone recovery typically begins within 2-4 weeks. SERM (clomiphene or tamoxifen) co-administration is sometimes used to sustain LH sensitivity following the triptorelin flare.
Research protocols only. Critical: single dose only for PCT use, do not repeat. Not medical advice.
Drug Interactions
Safety Profile
Triptorelin has FDA approval (depot) and established clinical safety.
Single-dose PCT safety: The 100 mcg aqueous dose is far below the oncology depot doses (3,750-11,250 mcg). Safety data at this dose level is limited to case reports and community observational use.
Critical: do not repeat dose: A second injection within days to weeks initiates the downregulation phase, causing testosterone suppression rather than stimulation. Single shot only for PCT application.
Testosterone flare before drop: In prostate cancer patients, initial triptorelin causes a testosterone flare before castration, monitor for androgen-dependent symptoms during first injection.
FDA approved for oncology: Full Phase III safety data available for depot formulations at much higher doses than PCT use.
References
- [1]Crawford ED, et al. "Triptorelin depot formulations for prostate cancer." Drugs. 2002;62(3):425-437.
- [2]Tan RS, Matern B. "Triptorelin for PCT after androgenic anabolic steroids: case report and review." J Int Soc Sports Nutr. 2019.